Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KIR3DL2-targeted CAR-T cell therapy
- Development stage
- Preclinical
- Lead developer
- Peter MacCallum Cancer Centre
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
KIR3DL2-targeted CAR-T cell therapy is an investigational, preclinical-stage cellular immunotherapy designed to treat T-cell lymphomas (TCL). It utilizes chimeric antigen receptor (CAR) T cells engineered to recognize KIR3DL2 (CD158k), a killer cell immunoglobulin-like receptor that is highly and specifically expressed on malignant T cells in cutaneous T-cell lymphoma (CTCL)—including Sézary syndrome and mycosis fungoides—and peripheral T-cell lymphoma (PTCL). Because KIR3DL2 expression is minimal on healthy T and NK cells, this therapy aims to minimize on-target, off-tumor toxicity. Research groups, such as those at the Peter MacCallum Cancer Centre, are also developing allogeneic ("off-the-shelf") versions using CRISPR-HDR technology to insert the CAR gene into the TRAC locus while modifying the B2M/HLA-E loci to prevent graft-versus-host disease and rejection.
- Other names
- KIR3DL2-CAR-T cellsKIR-3DL2-CAR-T cellsKIR 3DL2-CAR-T cellsKIR-CAR-T cellsCD158k-targeted CAR-T cell therapyCD-158k-targeted CAR-T cell therapyCD 158k-targeted CAR-T cell therapy
02
Targets
KIR3DL2 (Killer cell immunoglobulin-like receptor 3DL2)
Beyond the preview
Go deeper on KIR3DL2-targeted CAR-T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KIR3DL2-targeted CAR-T cell therapy.